Replies to post #180 on Huifeng Bio-pharmaceutical Technology (fka HFGB)

[pappy]

I am glad the SEC only found this minor infraction which had no effect on cashflow.

So reported eps for 2009 were adjusted down to $0.12 from the previous reported $0.15 due to warrants not being expense properly.

HFGB is a play on $20 million of additional capacity coming on line to service a growing backlog.

I am glad to see they are taking this time to get their books in order.

This may turn out to be a buying opportunity although I will not be buying anymore Chinese stocks until the market values them fairly.